Stockscreener 앱 받기
99.73
4.09%
-4.25
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella’s QTORIN pipeline targets a breakout moment in rare skin care - MSN
Analyst Calls: Is Palvella Therapeutics Inc stock forming a cup and handle2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December - MarketBeat
Pharma News: Is Palvella Therapeutics Inc a turnaround storyWeekly Investment Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Moving Averages: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aug Action: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aspiriant LLC Acquires Shares of 5,852 Palvella Therapeutics, Inc. $PVLA - Defense World
Palvella Highlights QTORIN Pipeline and 2026 Growth Outlook - TipRanks
Palvella Therapeutics, Inc. Advances Rare Disease Therapies - TradingView — Track All Markets
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics provides corporate update and 2026 outlook - marketscreener.com
Palvella Therapeutics Provides Corporate Update And 2026 Outlook - TradingView — Track All Markets
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies - The Manila Times
A new gel that could become the first treatment for rare skin diseases - Stock Titan
Palvella Taps Veteran Dermatology Executive to Steer Medical Affairs Push - MyChesCo
Will Palvella Therapeutics Inc. (PI6) stock benefit from commodity supercycleForecast Cut & Proven Capital Preservation Methods - Улправда
Will Palvella Therapeutics Inc. stock maintain growth storyMarket Growth Summary & Low Drawdown Investment Ideas - Улправда
Palvella Therapeutics stock maintains Buy rating at TD Cowen ahead of key trial data - Investing.com Canada
Why analysts recommend Palvella Therapeutics Inc. (PI6) stockJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - Улправда
What is the fair value of Palvella Therapeutics Inc. stock now2025 Support & Resistance & Verified Technical Trade Signals - ulpravda.ru
Will Palvella Therapeutics Inc. stock pay special dividendsPortfolio Return Report & Low Risk High Reward Ideas - Улправда
BTIG Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics, Inc. (PVLA) Stock Analysis: Unveiling an 82% Potential Upside in Biotech - DirectorsTalk Interviews
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Mizuho - Defense World
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - MyChesCo
Aug Swings: Will Palvella Therapeutics Inc stock maintain growth storyJuly 2025 Technicals & High Accuracy Buy Signal Tips - moha.gov.vn
Mizuho Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.5%Here's What Happened - MarketBeat
Palvella Therapeutics Appoints Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - citybiz
Palvella Therapeutics Strengthens Leadership Team with - GlobeNewswire
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - Sahm
Mizuho initiates coverage on Palvella Therapeutics stock with Outperform rating - Investing.com Canada
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Stock Watch: Biotech Acquisitions Drive Sector Momentum Going Into 2026 - Citeline News & Insights
Earnings Recap: Will Palvella Therapeutics Inc stock pay special dividendsEarnings Recap Report & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Palvella Therapeutics (NASDAQ:PVLA) Trading Down 4.9% – What’s Next? - Defense World
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - MSN
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 4.9%Here's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 3.9% – Still a Buy? - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 3.9%Should You Buy? - MarketBeat
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Should You Buy? - Defense World
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock enhance shareholder valueSector-Based Investing & Free Proven Portfolio Growth Strategies - Bollywood Helpline
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1%Time to Buy? - MarketBeat
Aclaris Joins Nasdaq Biotech Index, Marking Milestone for Clinical-Stage Firm - MyChesCo
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 5.9%Here's What Happened - MarketBeat
Published on: 2025-12-23 22:49:55 - bollywoodhelpline.com
FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path - MyChesCo
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha
Rare disease breakthrough? Palvella reports strong phase 2 results - MSN
Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results - MyChesCo
Palvella Therapeutics stock hits 52-week high at 112.4 USD By Investing.com - Investing.com Nigeria
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week HighStill a Buy? - MarketBeat
Palvella Therapeutics stock hits 52-week high at 112.4 USD - Investing.com
Palvella Therapeutics, Inc.(NasdaqCM:PVLA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Palvella Therapeutics (PVLA) Price Target Increased by 33.50% to 178.50 - Nasdaq
Adagene, Palvella gain after FDA fast track designations - MSN
4.73%
0.92%
자본화:
|
볼륨(24시간):